<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02538900</url>
  </required_header>
  <id_info>
    <org_study_id>STU00105855</org_study_id>
    <secondary_id>1R01HL122846-01</secondary_id>
    <nct_id>NCT02538900</nct_id>
  </id_info>
  <brief_title>Low InTensity Exercise Intervention in PAD</brief_title>
  <acronym>LITE</acronym>
  <official_title>Low InTensity Exercise Intervention in PAD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This proposed study will determine whether a home-based exercise intervention that avoids&#xD;
      continuous supervision and exercise-related ischemic pain improves walking performance at&#xD;
      52-week follow-up in people with PAD, compared to an attention control group and compared to&#xD;
      a high intensity exercise intervention. In our secondary aims, we will determine whether high&#xD;
      intensity exercise improves six-minute walk distance as compared to the attention control&#xD;
      group. In secondary aims, we will also determine whether low intensity exercise and high&#xD;
      intensity home-based exercise, respectively, improve patient reported outcomes, physical&#xD;
      activity, and treadmill walking performance compared to attention control. Our intervention&#xD;
      directly addresses two aspects of current practice guidelines that are major barriers to&#xD;
      exercise for patients with PAD: 1) the recommendation for supervised exercise and 2) the&#xD;
      recommendation for high intensity ischemic-pain inducing walking exercise.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We will randomize 305 PAD participants to one of three parallel arms: Group 1: Low-intensity,&#xD;
      self-paced walking exercise; Group 2: Standard high intensity, ischemic pain-inducing walking&#xD;
      exercise; Group 3: Non-exercising attention control group. The low and high intensity&#xD;
      exercise groups will attend center-based exercise sessions once per week for four weeks&#xD;
      followed by transition to an entirely home-based exercise program for an additional 48 weeks&#xD;
      (52 weeks total). Coaches will contact participants weekly by telephone after the first four&#xD;
      weeks of the intervention. The low and high intensity exercise interventions will use&#xD;
      identical self-regulatory and support strategies. However, the low intensity exercise group&#xD;
      will be instructed to exercise with minimal to no ischemic leg discomfort and the high&#xD;
      intensity group will be instructed to exercise to maximal ischemic leg pain. These two&#xD;
      distinct exercise prescriptions will be reinforced during 48 weeks of home-based exercise,&#xD;
      using a well-validated behavioral coaching model that can be delivered by telephone once&#xD;
      weekly. Our primary outcome is change in six-minute walk distance at 52-week follow-up. If&#xD;
      our hypotheses are correct, millions of people with PAD will benefit from this alternative&#xD;
      exercise regimen which will be accessible to most of the 8 million people in the U.S. who&#xD;
      suffer from PAD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">October 19, 2020</completion_date>
  <primary_completion_date type="Actual">October 19, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Individuals collecting the outcome assessment will not be aware of group assignment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Six-minute Walk Distance</measure>
    <time_frame>change from baseline to week 52</time_frame>
    <description>In the six-minute walk, participants walk back and forth along a 100-ft hallway for six minutes after standardized instructions to complete as many laps as possible. Distance covered in six minutes is recorded.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Six-minute Walk Distance</measure>
    <time_frame>change from baseline to week 26</time_frame>
    <description>In the six-minute walk, participants walk back and forth along a 100-ft hallway for six minutes after standardized instructions to complete as many laps as possible. Distance covered in six minutes is recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximal Treadmill Walking Time</measure>
    <time_frame>change from baseline to week 52</time_frame>
    <description>In the treadmill walking test, participants walk on either a gardner or modified gardner protocol until they stop the test. Time walked is recorded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical Activity Levels</measure>
    <time_frame>Change from baseline to week 52</time_frame>
    <description>ActiGraph measured physical activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Walking Impairment Questionnaire (WIQ) Distance and Speed Score.</measure>
    <time_frame>change from baseline to week 52</time_frame>
    <description>The WIQ is a well validated questionnaire that measures patient-reported walking limitations in distance and speed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related Quality of Life Measure</measure>
    <time_frame>change from baseline to week 52</time_frame>
    <description>The SF-36 physical functioning score will be used to measure quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence to Intervention</measure>
    <time_frame>from baseline to week 52</time_frame>
    <description>Adherence is defined as the proportion achieving at least 80% of the prescribed exercise frequency and duration during the final month of the intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Muscle Biopsy Measures of Mitochondrial Oxidative Metabolism and Oxidative Stress.</measure>
    <time_frame>change from baseline to week 52</time_frame>
    <description>Muscle tissue will be collected at baseline and follow up to measures Change in muscle biopsy measures of mitochondrial oxidative metabolism and oxidative stress.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Qualitative Assessment</measure>
    <time_frame>At 52 week follow up</time_frame>
    <description>We will use qualitative methods to explore participants' perceptions of the exercise interventions in the high and low-intensity exercise groups, respectively.</description>
  </other_outcome>
  <other_outcome>
    <measure>Physical Activity Levels Over Seven Days</measure>
    <time_frame>26 week follow-up.</time_frame>
    <description>ActiGraph</description>
  </other_outcome>
  <other_outcome>
    <measure>WIQ Distance and Speed Score</measure>
    <time_frame>26 week follow-up</time_frame>
    <description>The WIQ is a well validated questionnaire that measures patient-reported walking limitations in distance and speed.</description>
  </other_outcome>
  <other_outcome>
    <measure>Health Related Quality of Life</measure>
    <time_frame>26 weeks</time_frame>
    <description>SF-36 physical functioning score.</description>
  </other_outcome>
  <other_outcome>
    <measure>Adherence to Assigned Intervention</measure>
    <time_frame>26 weeks.</time_frame>
    <description>Adherence is defined as the proportion achieving at least 80% of the prescribed exercise frequency and duration during the final month of the intervention.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">305</enrollment>
  <condition>Peripheral Artery Disease</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low-intensity, self-paced walking exercise. Home based exercise.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard high intensity, ischemic pain-inducing walking exercise. Home based exercise.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Non-exercising attention control group. Contact with staff at same frequency as exercise groups, but staff deliver information on health not related to exercise.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Exercise</intervention_name>
    <description>Participants in one of the exercise intervention groups will attend once weekly sessions at the medical center for the first four weeks of the study (Weeks 1-4, Phase I). During weeks 5-52 (Phase II), they will receive weekly telephone calls from a study coach.</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Attention control</intervention_name>
    <description>Our attention control group controls for the possibility that regular contact with the study team may improve outcomes in participants randomized to the intervention. Participants randomized to the control group will attend weekly one-hour educational sessions at Northwestern University for the first four weeks of the intervention (Phase I). These sessions are on topics of interest to the typical PAD patient and are led by physicians and other health care workers. Topics include Medicare Part D, nutritional supplements, and cancer screening. During Phase II (weeks 5-52), the attention control group will receive weekly telephone calls, lasting 5-15 minutes, with information on a health-related topic.</description>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        All participants will have PAD. PAD will be defined as follows. First, an ABI &lt; or = 0.90&#xD;
        at the baseline study visit is a well-accepted standard for the diagnosis of PAD and will&#xD;
        be an inclusion criterion. Second, people with an ABI of &gt;0.90 and &lt; or = 1.00 who&#xD;
        experience a 20% ankle systolic pressure drop after the heel-rise test will also be&#xD;
        included. Third, potential participants with an ABI &gt; 0.90 who have vascular lab evidence&#xD;
        of PAD or angiographic evidence of PAD who have ischemic symptoms during the six-minute&#xD;
        walk and/or treadmill exercise stress test will be eligible. In addition to meeting a&#xD;
        criterion for PAD, all participants must be symptomatic, defined by one of the following&#xD;
        criteria:; a) ischemic leg symptoms (primarily assessed with the San Diego Claudication&#xD;
        Questionnaire); b) report ischemic leg symptoms at the end of the six-minute walk; c)&#xD;
        report ischemic leg symptoms at the end of the baseline treadmill stress test; d) walking&#xD;
        impairment questionnaire results, e) interview with the potential participant about the&#xD;
        presence and nature of leg symptoms during walking activity.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Above or below knee amputation, critical limb ischemia, wheelchair confinement, or&#xD;
             foot ulcer.&#xD;
&#xD;
          2. Individuals whose walking is limited by a condition other than PAD.&#xD;
&#xD;
          3. &gt; Class II NYHA heart failure or angina. Increase in angina, angina at rest, or&#xD;
             abnormal baseline treadmill stress test.&#xD;
&#xD;
          4. Major surgery including lower extremity revascularization or orthopedic surgery during&#xD;
             the prior three months or anticipated in the next twelve months.&#xD;
&#xD;
          5. Major medical illness including renal disease requiring dialysis, lung disease&#xD;
             requiring oxygen other than at night, or cancer (other than non-melanoma skin cancer)&#xD;
             requiring treatment in the prior three years. Potential participants may still qualify&#xD;
             if they have had treatment for early stage cancer in the previous three years and the&#xD;
             prognosis is excellent.&#xD;
&#xD;
          6. Mini-mental status examination score &lt;23, dementia, or psychiatric illness including&#xD;
             severe depression or anxiety. Investigator discretion may be used to allow some people&#xD;
             with an MMSE below 23 to participate if the investigator determines there is another&#xD;
             reason for their lower score, including lack of sufficient familiarity with the&#xD;
             English language or lack of sufficient education to achieve a score of 23 or higher.&#xD;
&#xD;
          7. Currently walking regularly for exercise at a level comparable to the amount of&#xD;
             exercise prescribed in the intervention.&#xD;
&#xD;
          8. Current or recent (within 3 months) participation in another clinical trial or cardiac&#xD;
             rehabilitation. For a clinical trial of a stem cell or gene therapy intervention,&#xD;
             potential participants will be potentially eligible immediately after the final study&#xD;
             visit for the clinical trial, so long as long as at least six months has passed since&#xD;
             the participant received their final treatment in the stem cell or gene therapy&#xD;
             intervention. For a clinical trial involving open-label therapy in which the treatment&#xD;
             is not related to functional performance and will not change during the LITE Trial,&#xD;
             participants may still qualify for the LITE Trial based on investigator discretion.&#xD;
&#xD;
          9. Individuals with PAD who have a history of lower extremity revascularization and have&#xD;
             a normal ABI.&#xD;
&#xD;
         10. Individuals who are not able to walk for exercise at a sufficiently slow pace to avoid&#xD;
             ischemic leg symptoms.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary McDermott, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ochsner Baptist, Tulane University</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 31, 2015</study_first_submitted>
  <study_first_submitted_qc>September 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2015</study_first_posted>
  <results_first_submitted>October 18, 2021</results_first_submitted>
  <results_first_submitted_qc>October 18, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">November 16, 2021</results_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Mary McDermott</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>peripheral arterial disease, peripheral artery disease, PAD, exercise</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 16, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/00/NCT02538900/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group 1</title>
          <description>Low-intensity, self-paced walking exercise. Home based exercise.&#xD;
Exercise: Participants in one of the exercise intervention groups will attend once weekly sessions at the medical center for the first four weeks of the study (Weeks 1-4, Phase I). During weeks 5-52 (Phase II), they will receive weekly telephone calls from a study coach.</description>
        </group>
        <group group_id="P2">
          <title>Group 2</title>
          <description>Standard high intensity, ischemic pain-inducing walking exercise. Home based exercise.&#xD;
Exercise: Participants in one of the exercise intervention groups will attend once weekly sessions at the medical center for the first four weeks of the study (Weeks 1-4, Phase I). During weeks 5-52 (Phase II), they will receive weekly telephone calls from a study coach.</description>
        </group>
        <group group_id="P3">
          <title>Group 3</title>
          <description>Non-exercising attention control group. Contact with staff at same frequency as exercise groups, but staff deliver information on health not related to exercise.&#xD;
Attention control: Our attention control group controls for the possibility that regular contact with the study team may improve outcomes in participants randomized to the intervention. Participants randomized to the control group will attend weekly one-hour educational sessions at Northwestern University for the first four weeks of the intervention (Phase I). These sessions are on topics of interest to the typical PAD patient and are led by physicians and other health care workers. Topics include Medicare Part D, nutritional supplements, and cancer screening. During Phase II (weeks 5-52), the attention control group will receive weekly telephone calls, lasting 5-15 minutes, with information on a health-related topic.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="116"/>
                <participants group_id="P2" count="124"/>
                <participants group_id="P3" count="65"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="96"/>
                <participants group_id="P2" count="106"/>
                <participants group_id="P3" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1</title>
          <description>Low-intensity, self-paced walking exercise. Home based exercise.&#xD;
Exercise: Participants in one of the exercise intervention groups will attend once weekly sessions at the medical center for the first four weeks of the study (Weeks 1-4, Phase I). During weeks 5-52 (Phase II), they will receive weekly telephone calls from a study coach.</description>
        </group>
        <group group_id="B2">
          <title>Group 2</title>
          <description>Standard high intensity, ischemic pain-inducing walking exercise. Home based exercise.&#xD;
Exercise: Participants in one of the exercise intervention groups will attend once weekly sessions at the medical center for the first four weeks of the study (Weeks 1-4, Phase I). During weeks 5-52 (Phase II), they will receive weekly telephone calls from a study coach.</description>
        </group>
        <group group_id="B3">
          <title>Group 3</title>
          <description>Non-exercising attention control group. Contact with staff at same frequency as exercise groups, but staff deliver information on health not related to exercise.&#xD;
Attention control: Our attention control group controls for the possibility that regular contact with the study team may improve outcomes in participants randomized to the intervention. Participants randomized to the control group will attend weekly one-hour educational sessions at Northwestern University for the first four weeks of the intervention (Phase I). These sessions are on topics of interest to the typical PAD patient and are led by physicians and other health care workers. Topics include Medicare Part D, nutritional supplements, and cancer screening. During Phase II (weeks 5-52), the attention control group will receive weekly telephone calls, lasting 5-15 minutes, with information on a health-related topic.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="116"/>
            <count group_id="B2" value="124"/>
            <count group_id="B3" value="65"/>
            <count group_id="B4" value="305"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.8" spread="10.1"/>
                    <measurement group_id="B2" value="68.8" spread="8.7"/>
                    <measurement group_id="B3" value="69.5" spread="10.1"/>
                    <measurement group_id="B4" value="69.3" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="146"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="181"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="114"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="116"/>
                    <measurement group_id="B2" value="124"/>
                    <measurement group_id="B3" value="65"/>
                    <measurement group_id="B4" value="305"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ankle-brachial index</title>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.66" spread="0.17"/>
                    <measurement group_id="B2" value="0.67" spread="0.15"/>
                    <measurement group_id="B3" value="0.67" spread="0.15"/>
                    <measurement group_id="B4" value="0.66" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.3" spread="6.7"/>
                    <measurement group_id="B2" value="31.1" spread="7.3"/>
                    <measurement group_id="B3" value="30.8" spread="7.3"/>
                    <measurement group_id="B4" value="30.7" spread="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Six-min walk distance</title>
          <units>meters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="326" spread="99"/>
                    <measurement group_id="B2" value="329" spread="101"/>
                    <measurement group_id="B3" value="328" spread="87"/>
                    <measurement group_id="B4" value="328" spread="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Six-minute Walk Distance</title>
        <description>In the six-minute walk, participants walk back and forth along a 100-ft hallway for six minutes after standardized instructions to complete as many laps as possible. Distance covered in six minutes is recorded.</description>
        <time_frame>change from baseline to week 52</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Low-intensity, self-paced walking exercise. Home based exercise.&#xD;
Exercise: Participants in one of the exercise intervention groups will attend once weekly sessions at the medical center for the first four weeks of the study (Weeks 1-4, Phase I). During weeks 5-52 (Phase II), they will receive weekly telephone calls from a study coach.</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Standard high intensity, ischemic pain-inducing walking exercise. Home based exercise.&#xD;
Exercise: Participants in one of the exercise intervention groups will attend once weekly sessions at the medical center for the first four weeks of the study (Weeks 1-4, Phase I). During weeks 5-52 (Phase II), they will receive weekly telephone calls from a study coach.</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>Non-exercising attention control group. Contact with staff at same frequency as exercise groups, but staff deliver information on health not related to exercise.&#xD;
Attention control: Our attention control group controls for the possibility that regular contact with the study team may improve outcomes in participants randomized to the intervention. Participants randomized to the control group will attend weekly one-hour educational sessions at Northwestern University for the first four weeks of the intervention (Phase I). These sessions are on topics of interest to the typical PAD patient and are led by physicians and other health care workers. Topics include Medicare Part D, nutritional supplements, and cancer screening. During Phase II (weeks 5-52), the attention control group will receive weekly telephone calls, lasting 5-15 minutes, with information on a health-related topic.</description>
          </group>
        </group_list>
        <measure>
          <title>Six-minute Walk Distance</title>
          <description>In the six-minute walk, participants walk back and forth along a 100-ft hallway for six minutes after standardized instructions to complete as many laps as possible. Distance covered in six minutes is recorded.</description>
          <units>meters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
                <count group_id="O2" value="124"/>
                <count group_id="O3" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.4" lower_limit="-21.5" upper_limit="8.8"/>
                    <measurement group_id="O2" value="34.5" lower_limit="20.1" upper_limit="48.9"/>
                    <measurement group_id="O3" value="-15.1" lower_limit="-35.8" upper_limit="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Six-minute Walk Distance</title>
        <description>In the six-minute walk, participants walk back and forth along a 100-ft hallway for six minutes after standardized instructions to complete as many laps as possible. Distance covered in six minutes is recorded.</description>
        <time_frame>change from baseline to week 26</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximal Treadmill Walking Time</title>
        <description>In the treadmill walking test, participants walk on either a gardner or modified gardner protocol until they stop the test. Time walked is recorded</description>
        <time_frame>change from baseline to week 52</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Physical Activity Levels</title>
        <description>ActiGraph measured physical activity</description>
        <time_frame>Change from baseline to week 52</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Walking Impairment Questionnaire (WIQ) Distance and Speed Score.</title>
        <description>The WIQ is a well validated questionnaire that measures patient-reported walking limitations in distance and speed.</description>
        <time_frame>change from baseline to week 52</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health-related Quality of Life Measure</title>
        <description>The SF-36 physical functioning score will be used to measure quality of life.</description>
        <time_frame>change from baseline to week 52</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adherence to Intervention</title>
        <description>Adherence is defined as the proportion achieving at least 80% of the prescribed exercise frequency and duration during the final month of the intervention.</description>
        <time_frame>from baseline to week 52</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Muscle Biopsy Measures of Mitochondrial Oxidative Metabolism and Oxidative Stress.</title>
        <description>Muscle tissue will be collected at baseline and follow up to measures Change in muscle biopsy measures of mitochondrial oxidative metabolism and oxidative stress.</description>
        <time_frame>change from baseline to week 52</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Qualitative Assessment</title>
        <description>We will use qualitative methods to explore participants' perceptions of the exercise interventions in the high and low-intensity exercise groups, respectively.</description>
        <time_frame>At 52 week follow up</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Physical Activity Levels Over Seven Days</title>
        <description>ActiGraph</description>
        <time_frame>26 week follow-up.</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>WIQ Distance and Speed Score</title>
        <description>The WIQ is a well validated questionnaire that measures patient-reported walking limitations in distance and speed.</description>
        <time_frame>26 week follow-up</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Health Related Quality of Life</title>
        <description>SF-36 physical functioning score.</description>
        <time_frame>26 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Adherence to Assigned Intervention</title>
        <description>Adherence is defined as the proportion achieving at least 80% of the prescribed exercise frequency and duration during the final month of the intervention.</description>
        <time_frame>26 weeks.</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected monthly through out the 12-month intervention period.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group 1</title>
          <description>Low-intensity, self-paced walking exercise. Home based exercise.&#xD;
Exercise: Participants in one of the exercise intervention groups will attend once weekly sessions at the medical center for the first four weeks of the study (Weeks 1-4, Phase I). During weeks 5-52 (Phase II), they will receive weekly telephone calls from a study coach.</description>
        </group>
        <group group_id="E2">
          <title>Group 2</title>
          <description>Standard high intensity, ischemic pain-inducing walking exercise. Home based exercise.&#xD;
Exercise: Participants in one of the exercise intervention groups will attend once weekly sessions at the medical center for the first four weeks of the study (Weeks 1-4, Phase I). During weeks 5-52 (Phase II), they will receive weekly telephone calls from a study coach.</description>
        </group>
        <group group_id="E3">
          <title>Group 3</title>
          <description>Non-exercising attention control group. Contact with staff at same frequency as exercise groups, but staff deliver information on health not related to exercise.&#xD;
Attention control: Our attention control group controls for the possibility that regular contact with the study team may improve outcomes in participants randomized to the intervention. Participants randomized to the control group will attend weekly one-hour educational sessions at Northwestern University for the first four weeks of the intervention (Phase I). These sessions are on topics of interest to the typical PAD patient and are led by physicians and other health care workers. Topics include Medicare Part D, nutritional supplements, and cancer screening. During Phase II (weeks 5-52), the attention control group will receive weekly telephone calls, lasting 5-15 minutes, with information on a health-related topic.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Lower extremity revascularization</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="116"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="124"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Ischemic heart disease</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="116"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Stroke or cerebral hemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="116"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="124"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Heart failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Carotid revascularization</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="116"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="116"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="124"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Abdominal problem</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="116"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Diabetes</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="116"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="124"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>GI bleed</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="124"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Fall or fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="116"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Pulmonary event</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="116"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Elective surgery</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="116"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="124"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="116"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Coronary revascularization</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="116"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Lightheaded</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="116"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Venous thromboembolism</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="116"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="116"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Abdominal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Acute renal failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="116"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Esophageal problem</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>PAD</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Angina</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Bowel obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Complication from angiogram</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Complication from medical procedure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Congestive heart failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Diagnostic testing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Electrolyte problem</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Medication side effect</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Mental status</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Musculoskeletal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Neurologic problem</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Pleural effusions</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Psychiatric</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Testicular problem</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="116"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="124"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Critical limb ischemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="116"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>New or increased chest discomfort during activity or exercise</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="116"/>
                <counts group_id="E2" events="23" subjects_affected="16" subjects_at_risk="124"/>
                <counts group_id="E3" events="14" subjects_affected="8" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>New or increased shortness of breath during activity or exercise</sub_title>
                <counts group_id="E1" events="21" subjects_affected="13" subjects_at_risk="116"/>
                <counts group_id="E2" events="38" subjects_affected="24" subjects_at_risk="124"/>
                <counts group_id="E3" events="30" subjects_affected="19" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>New or increased dizziness or generalized weakness during activity or exercise</sub_title>
                <counts group_id="E1" events="25" subjects_affected="23" subjects_at_risk="116"/>
                <counts group_id="E2" events="28" subjects_affected="21" subjects_at_risk="124"/>
                <counts group_id="E3" events="42" subjects_affected="22" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mary McDermott MD</name_or_title>
      <organization>Northwestern University</organization>
      <phone>312-503-6419</phone>
      <email>mdm608@northwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

